What is the current valuation of the UK respiratory drugs market?

The market valuation was $1788.75 Million in 2024. Read More

What is the projected market size for the UK respiratory drugs market by 2035?

The market is expected to reach $3503.0 Million by 2035. Read More

What is the expected CAGR for the UK respiratory drugs market during the forecast period 2025 - 2035?

The expected CAGR is 6.3% during the forecast period. Read More

Which drug class had the highest valuation in the UK respiratory drugs market in 2024?

Inhaled Corticosteroids (ICS) had the highest valuation, ranging from $600.0 Million to $1200.0 Million. Read More

Which distribution channel generated the highest revenue in the UK respiratory drugs market in 2024?

Retail Pharmacies generated the highest revenue, with a valuation between $800.0 Million and $1500.0 Million. Read More

What is the market valuation range for Chronic Obstructive Pulmonary Disease (COPD) in 2024?

The market valuation for COPD ranged from $800.0 Million to $1600.0 Million in 2024. Read More

What is the expected growth trend for the Inhalation route of administration in the UK respiratory drugs market?

The Inhalation route is projected to grow, with a valuation range of $1070.0 Million to $2100.0 Million. Read More

How does the market for Combination Drugs compare to other drug classes in 2024?

Combination Drugs had a valuation range of $300.0 Million to $600.0 Million, indicating a competitive position among drug classes. Read More

What is the valuation range for Antihistamines in the UK respiratory drugs market in 2024?

Antihistamines had a valuation range of $100.0 Million to $200.0 Million in 2024. Read More

UK Respiratory Drugs Market

Q: What are the key players in the UK respiratory drugs market?

Key players include Pfizer, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceutical Industries, Merck & Co., Sanofi, and Roche. Read More

ID: MRFR/Pharma/43767-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

UK Respiratory Drugs Market Research Report By Drug Class (Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs, Others), By Disease Type (Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion, Others), By Route of Administration (Inhalation, Enteral, Parenteral) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth & Industry Forecast 2025 To 2035

UK Respiratory Drugs Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.3%

2024 Market Size$ 1,788.75 Million

2025 Market Size$ 1,901.44 Million

2035 Market Size$ 3,503 Million

Key Players

Pfizer

Boehringer Ingelheim

GlaxoSmithKline

AstraZeneca

Novartis

Teva Pharmaceutical Industries

Trends

Increased Focus on Personalized Medicine
Rise of Biologics and Biosimilars
Integration of Digital Health Solutions

Opportunities

Rising Healthcare Expenditure
Growing Prevalence of Respiratory Diseases
Regulatory Support for Innovative Therapies

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Drug Class (USD Million)
  1. 4.1.1 Short-Acting Beta2-Agonists (SABA)
  2. 4.1.2 Long-Acting Beta2-Agonists (LABA)
  3. 4.1.3 Inhaled Corticosteroids (ICS)
  4. 4.1.4 Anticholinergics
  5. 4.1.5 Antihistamines
  6. 4.1.6 Vasodilators
  7. 4.1.7 Combination Drugs
  8. 4.1.8 Others
2. 4.2 Industrial Automation & Equipment, BY Disease Type (USD Million)
  1. 4.2.1 Asthma
  2. 4.2.2 Chronic Bronchitis
  3. 4.2.3 Chronic Obstructive Pulmonary Disease (COPD)
  4. 4.2.4 Pleural Effusion
  5. 4.2.5 Others
3. 4.3 Industrial Automation & Equipment, BY Route of Administration (USD Million)
  1. 4.3.1 Inhalation
  2. 4.3.2 Enteral
  3. 4.3.3 Parenteral
4. 4.4 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Teva Pharmaceutical Industries (IL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY DRUG CLASS
3. 6.3 UK MARKET ANALYSIS BY DISEASE TYPE
4. 6.4 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE TYPE, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Drug Class (USD Million, 2025-2035)

Short-Acting Beta2-Agonists (SABA)
Long-Acting Beta2-Agonists (LABA)
Inhaled Corticosteroids (ICS)
Anticholinergics
Antihistamines
Vasodilators
Combination Drugs
Others

Industrial Automation & Equipment By Disease Type (USD Million, 2025-2035)

Asthma
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)
Pleural Effusion
Others

Industrial Automation & Equipment By Route of Administration (USD Million, 2025-2035)

Inhalation
Enteral
Parenteral

Industrial Automation & Equipment By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”